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Background & objectives: Malaria is one of the major public health problems in the north eastern
region of India. Antimalarial drug resistance is widespread and one of the important causes of
recent resurgence of falciparum malaria in this region. Antimalarial drugs are seen to be used
sequentially one after another in many areas of the region, when therapeutic failure is  observed
with a drug. In view of this, the present study was undertaken to assess the therapeutic efficacy of
common antimalarial drugs viz., chloroquine, sulfadoxine+pyrimethamine (S-P) and quinine,
administered sequentially to the patients with Plasmodium falciparum infection in a Myanmar
bordering area of Arunachal Pradesh.
Methods: A hospital based in vivo study was carried out with 53 patients with uncomplicated falciparum
malaria. All patients were first treated with chloroquine and therapeutic efficacy assessed. In case of
therapeutic failure of chloroquine combination drug (S-P) was given and those showing failure with
S-P combination, oral quinine was administered and followed up for 28 days to assess both clinical and
parasitological responses.
Results: Therapeutic failure was observed with chloroquine in 83.1 per cent (44 of 53) and to both
chloroquine and S-P combination drug in 44.1 per cent (19/43) patients. Further, 15.8 per cent patients
(3 of 19) failed to respond even to quinine. Overall, 5.7 per cent patients (3 of 53) showed unresponsiveness
to all the three drugs i.e., chloroquine, S-P combination and quinine. Asexual parasite clearance and
also fever clearance was slowest with chloroquine and fastest with quinine.
Interpretation & conclusion: The findings of this study show the presence of multi drug failure
P. falciparum in Jairampur-Nampong, a western Myanmar bordering area of Arunachal Pradesh. Anti
malarial drug resistance is increasing in Indo-Myanmar border areas and systematic studies need to
be done to review the situation.
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The development and spread of drug resistant
falciparum malaria has been identified as a key factor in
the resurgence of malaria and one of the greatest
challenges to malaria control today1. Various factors
relating to drug, parasite and human host interactions
contribute to the development and spread of drug
resistance2 . Chloroquine resistance to Plasmodium
falciparum (Pf) appeared more or less simultaneously
during 1960 in Colombia (Latin America) and Thailand
(Southeast Asia) following which resistant Pf strains,
not only to chloroquine but also to other antimalarial drugs
like sulfadoxine+pyrimethamine (S-P) combination,
mefloquine and quinine, have been detected in most
countries of Southeast Asia region3. In India, the
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chloroquine resistant Pf first detected from Manja
primary health centre area of Assam in north eastern
region of India (NE India) in 19734, is widespread in all
the seven states of NE India as well as other parts of
the country5. Resistance to S-P combination drugs and
reduced efficacy to quinine has also been reported5,6
from many areas of NE India that shares a long
international border of about 3600 km with Bhutan, China,
Myanmar and Bangladesh. This region is highly
vulnerable for the importation of resistant strains from
neighbouring countries, particularly Myanmar where high
degree of Pf resistance to chloroquine, S-P combination
drugs and mefloquine has been reported from its western
parts bordering NE India 7. Chloroquine is still the first
line of treatment for malaria in most parts of NE India.
However, in many chloroquine resistant areas, the
alternate drug schedule has been introduced by Indian
National Anti Malaria Programme (NAMP) which
envisages treatment of fever cases with chloroquine
presumptively and administration of S-P combination
drug or quinine (if S-P combination fails) to
microscopically confirmed Pf cases8 practically ending
up in sequential treatment of falciparum malaria cases
with chloroquine, S-P combination drug and quinine.
Jairampur-Nampong area of district Changlang in
Arunachal Pradesh is a  Myanmar bordering area where
high degree of chloroquine resistance to Pf was detected
in 1982. Resistance to S-P combination drugs was also
recorded in adjoining areas  of Jairampur-Nampong in
the year 1992. Subsequently in 1995 this area was brought
under the alternate drug schedule of NAMP, India 5 .
Recently, a case of Pf malaria concurrently resistant to
chloroquine and S-P combination drug was reported from
Arunachal Pradesh raising concern about the possibility
of emergence of multi drug resistance in Pf in NE India 9.
Therefore, to assess the present status of therapeutic
efficacy of common antimalarial drugs for the treatment
of falciparum malaria, particularly the extent of multi
drug failure, the present study was carried out in
Jairampur-Nampong area of Arunachal Pradesh state,
India.
Material & Methods
Study area : The study was carried out in the
Government Hospital, Jairampur (27°18’N, 95°57’E),
Changlang district, Arunachal Pradesh, India located
at a distance of about 15 km from the western border
of Myanmar. Jairampur-Nampong area with about
35,000 population is historically  endemic for falciparum
malaria with an average annual parasite incidence of
25-50 per thousand population10 . People mainly
belonging to Tangsa ethnic group (>80%) reside on both
the sides of Indo-Myanmar border and have subsistence
farming as the main source of livelihood. This area is
under alternate drug (S-P combination) schedule of
NAMP, India since 1995.
Study subjects: The patients were selected among the
out door patients attending Jairampur hospital during 1999.
Patients above 1 yr of age, presenting with acute fever or
history of fever during the preceding 24 h, along with
microscopically confirmed P. falciparum mono-infection
having asexual parasite count between 1000-100,000/µl
without severe anaemia, as assessed by clinical
examination, were selected for the study after obtaining
written informed consent either from the patient (adult)
or from the parents or guardians in case of minors.
Patients having signs and symptoms of severe malaria 11
or danger signs as per WHO criteria 12 or those with severe
malnutrition or with any other concurrent infection or
disease or with known history of sulfonamide drug
sensitivity or having potential problem of follow up were
excluded from the study. Women with history of missed
periods were also excluded.
The study was approved by the Ethics Committee of
the Regional Medical Research Centre, (ICMR)
Dibrugarh, India.
Clinical and parasitological examination:  At the time
of enrollment a thorough physical examination of all
patients was done and blood was collected for smears
(thick & thin) after finger pricking in Jairampur hospital.
Axillary temperature was recorded with a standardized
digital thermometer. Blood slides were examined after
staining with 3 per cent Giemsa for 30 min. Asexual
parasites were counted against 300 leukocytes. The
parasite density was expressed as the number of  asexual
parasites/µl blood by assuming a mean normal leukocyte
count of 8000/µl.
Treatment regimen: All patients were given chloroquine
(25 mg/kg body weight) in 3 days (Day 0-10 mg, D1-10
mg, D2-5 mg) orally under direct supervision. Patients
were  monitored for vomiting, for about an hour, after
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administering the first dose of the drug. A replacement
dose was given, if necessary. Those patients who vomited
out the first as well as replacement dose of the drug
were not included in the study and were treated with i.v.
quinine in 5 per cent dextrose. Patients showing
therapeutic failure to chloroquine in absence of  signs
and symptoms of complicated Pf malaria or danger signs
were administered single oral dose of sulfadoxine
(25 mg/kg body weight) + pyrimethamine (1.25 mg/kg
body weight). Further, patients showing treatment failure
to both chloroquine and S-P combination drug in absence
of complications or danger signs or signs of toxicity were
administered oral quinine (10 mg/kg body weight) three
times a day for a period of 5 to 7 days, depending on the
compliance and tolerance. Patients showing failure even
to quinine were treated with mefloquine (15 mg/kg body
weight) single dose.
The antimalarial drugs used in the study were in good
condition and procured from NAMP, Guwahati office except
that of mefloquine that was used after procuring from the
open market as this drug is not supplied by the NAMP.
Parasitological and clinical response monitoring:
Chloroquine was given to the patients in the outpatient
department and after one hour of monitoring patients
were allowed to go home. However, patients were
admitted in the Government hospital, Jairampur for a
period of 7 days during the treatment with S-P
combination drug or quinine for close monitoring. Any
patient developing signs and symptoms of complication,
danger or toxicity sign was withdrawn from the study
and alternate treatment was given. All patients were
followed up for a period of 28 days after the treatment.
Monitoring of therapeutic efficacy was carried out
using the modified WHO protocol, 199612. Both thick
and thin blood smears as well as axillary temperature
was recorded on days 0, 2, 3, 7, 14, 21 and 28 in patients
treated with chloroquine and cases successively treated
with S-P combination drug (showing failure to
chloroquine) and quinine (showing failure to both
chloroquine and S-P combination drugs).
The clinical responses were classified as follows (i)
early treatment failure (ETF) :  if the patient developed
danger signs or severe malaria on or before day 3 in the
presence of asexual parasitaemia or when parasitaemia
on day 2 was higher than day 0 count irrespective of
axillary temperature or when parasitaemia on day 3 was
present with axillary temperature ³ 37.5°C or when
parasitaemia on day 3 was ³ 25 per cent of the count on
day 0, (ii) late treatment failure (LTF): development of
danger signs or severe malaria after day 3 or presence
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*All patients initially selected for the study were given chloroquine, **Chloroquine failure cases were treated S-P combination drug along with
primaquine, ***Chloroquine and S-P combination drug failure cases were treated with quinine
Table I. Characteristics of patients enrolled in therapeutic response study
Category Chloroquine* S-P combination drug**
Quinine***
  No. of patients 53 43 19
  Sex Male 38 30 15
Female 15 13 4
  Age (yr) Mean±SD 20.2±13.4 19.8±13.2 21.4±12.9
(range) (2.5-55) (2.6-55) (4.5-49)
Median 16.0 14.0 11.0
  Weight Mean±SD 39.6±14.8 39.1±15.2 41.1±14.3
  (kg) (range) (12-65) (13-65) (20-60)
  Ethnicity Tribal 30 26 13
Non-tribal 23 17 6
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of parasitaemia and axillary temperature ³ 37.5°C
between day 4-28 or presence of parasitaemia between
day 7-28, irrespective of axillary temperature ³ 37.5°C
and (iii) adequate clinical and parasitological response
(ACPR): absence of parasitaemia on day 28, irrespective
of axillary temperature, without previously meeting any
criteria of ETF or LTF.
Data analysis: The data were analyzed using EPI-Info
version 6.04d (Centres for Disease Control and
Prevention, Atlanta, USA). Geometrical means of
parasite density were calculated for persons with
detectable parasitaemia. Proportions were  compared
by Chi square text.
Results
A total of 891 patients with fever were screened for
malaria during the study period, of whom 265 were found
malaria positive [Pf-190, P. vivax, (Pv)-71, mixed
(Pv+Pf)-4]. Of these, a total of 58 consecutive patients
positive for Pf, satisfying the inclusion criteria, were
enrolled in the study. Fifty three patients completed the
chloroquine study (Table I) while 5 were lost to follow
up. In case of chloroquine, ACPR was found only in 9
(17%) patients; ETF and LTF together (n=44) gave a
failure rate of 83.1 per cent (Table II). Of the 44 patients
with chloroquine failure, one developed signs of cerebral
malaria on day 3 and was withdrawn from the study and
treated with quinine i.v. in 5 per cent dextrose. The
remaining 43 were treated with S-P combination drug.
On follow up, 24 patients (55.9%) showed adequate
clinical and parasitological response whereas 19 (44.1%)
showed therapeutic failure at various levels to S-P
combination drug (Table II). These 19 patients  were
administered oral quinine, only 8 could complete the full
7 days course of quinine while 11 patients could not
continue beyond 5 days having developed tinnitus,
dizziness and gastritis (n=7), nausea and vomiting (n=3)
on day 5, one patient refused to take quinine after day 5.
Tinnitus was developed in two patients who completed
the 7 days treatment. In 5 days quinine treatment group,
reduction in asexual parasitaemia was 20 per cent in
two patients  on day 3 as compared to day 0. However,
on day 7 both became asymptomatic but their asexual
parasite count was >25 per cent of the day 0 count. In 7
days quinine treatment group, only 1 failure at ETF level
was recorded both on days 3 and 7. Thus, the overall
failure rate of quinine was 15.8 per cent (3 out of 19) in
the study that was slightly higher (18.1%) in 5 days
treatment group than in 7 days treatment group (12.5%).
The 3 patients showing therapeutic failure to chloroquine,
S-P combination drug and quinine were treated with
mefloquine and their follow up for next 28 days showed
sensitivity to this drug. Overall, 83.1 per cent patients
were non-responsive to chloroquine alone, 35.8 per cent
failed to chloroquine and S-P combination both and in
5.7 per cent therapeutic failure to chloroquine, S-P
combination and quinine was noted.
The rate of asexual parasite clearance in patients on
different days of follow up was slowest with chloroquine
and fastest with quinine. The drop in parasitaemia after
2 days of treatment was about 32, 62 and 70 per cent in
chloroquine, S-P combination drug and quinine respectively.
After 2 days of treatment only 26.4 per cent patients were
found parasitaemic in case of quinine as compared to 67.4
and 98.1 per cent in S-P combination drug and chloroquine
respectively (P<0.000). On day 7, the proportion of
parasitaemic patients was 15.8, 17.2 and 47.6 per cent in
quinine, S-P combination and chloroquine treatment cases
respectively (P<0.02). The pattern of fever clearance in
the three groups was more or less similar to that of parasite
clearance on different days of follow up. However, in
patients treated with S-P combination drug a slight rise
in axillary temperature on days 2 and 3 was recorded
after a drop in temperature on day 1.
Discussion
Though the evolution and spread of drug resistance
is not fully understood it is  postulated that chloroquine
resistance in Asia was originated from a single focus in
the Cambodian area of Paillang near Thai border and
from there it spread to the surrounding areas 13 .
International border areas are particularly vulnerable for
importation and precipitation of drug resistant malaria
requiring special attention. In the Jairampur area
chloroquine resistance to the tune of 90 per cent with
about 60 per cent cases being RI type and 30 per cent
RII and RIII type (as per old WHO classification) was
detected5. In the present study though total failure rate of
chloroquine was nearly the same i.e., about 83 per cent,
the ETF (approximately equivalent to RII and RIII
resistance together) was about 60 per cent indicating
consolidation and stabilization of chloroquine resistance
during the intervening period. Similarly, the level of
resistance to S-P combination drug (5.3%) as found in
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19925 also seems to have gone up substantially to about
44 per cent therapeutic failure to S-P combination drug
in this study. Thus, within 4 yr of introduction of the
revised drug policy of NAMP (1995), S-P combination
drug in Jairampur-Nampong area has lost its
effectiveness to a great extent. Another disturbing aspect
is the persistence of parasitaemia up to day 3 in 15 per
cent cases treated by quinine after treatment failure with
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Table II. Therapeutic response of chloroquine and S-P combination drug
  Category Drug Characteristic Total ETF LTF ACPR Total
(%) (%) (%) failure
(%)
  No of cases CHQ 53 32 12 9 44
(60.4) (22.6) (17.0) (83.0)
SP 43 14 5 24 19
(32.6) (11.6) (55.8) (44.2)
  Age group CHQ £15 yr 25 16 5 4 21
>15 yr (64.0) (20.0) (16.0) (84.0)
28 16 7 5 23
(57.1) (25.0) (17.9) (82.1)
SP £15 yr 20 5 3 12 8
(25.0) (15.0) (60.0) (40.0)
>15 yr 23 9 2 12 11
(39.1) (8.7) (52.2) (47.8)
  Sex CHQ Male 38 23 4 8 30
(60.5) (10.5) (21.2) 78.9)
Female 15 9 5 1 14
(60.0) (33.3) (6.7) (93.3)
SP Male 30 12 4 14 16
(40.0) (13.3) (46.7) (53.3)
Female 13 2 1 10 3
(15.4) (7.7) (76.9) (23.1)
  Ethnicity CHQ Tribal 30 20 5 5 25
(66.7) (16.7) (16.7) (83.3)
Non-tribal 23 12 7 4 19
(52.2) (30.4) (17.4) 82.6)
SP Tribal 26 10 3 13 13
(38.5) (11.5) (50.0) (50.0)
Non-tribal 17 4 2 11 6
(23.5) (11.8) (64.7) (35.3)
  Geometric mean of asexual
CHQ
Day 0 value 5345 7745 4803 2879
  parasitaemia
  (per µl of blood)
SP
Day 0 value 3729 3876 4260 3521
CHQ - chloroquine treated patients; S-P - patients treated with sulfadoxine + pyremethamine combination drugs showing failure to chloroquine
treatment; ETF - Early treatment failure; LTF - Late treatment failure; ACPR - Adequate clinical and parasitological response
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both chloroquine and S-P combination drug. The plausible
reasons for such a  fast development of antimalarial drug
resistance in Jairampur-Nampong area could be the high
drug pressure in the presence of intense transmission,
particularly by Anopheles dirus  (considered well
adapted to drug resistant Pf strains) and frequent
population movement across Indo-Myanmar border.
These factors were considered as most favourable for
disseminating drug resistant Pf malaria from Thai-
Kampuchea border to other Southeast Asian countries14.
As this study was limited to only one site, it is difficult
to make any generalization. Nevertheless, the present
study unequivocally establishes the presence of strains
of P. falciparum  concurrently non-responsive to
chloroquine, S-P combination drug and quinine in
Myanmar bordering areas of Arunachal Pradesh.
Though quinine, at present, appears to be a satisfactory
drug for the treatment of Pf positive cases in this area,
poor compliance due to the potential toxicity of oral
quinine is a limiting factor in fully utilizing its potential to
treat uncomplicated falciparum cases. Moreover, its use
should be limited for the treatment of complicated cases
of falciparum malaria only. Exploratory research is
needed to enhance the effectiveness of S-P combination
drug and appropriate steps to delay the spread and further
consolidation of its resistance. Roll back malaria initiative
of WHO has emphasized on combination therapy as a
tool to enhance the effective life of an antimalaria 15.
Further, there is a need for a review of present drug
policy in border areas having the problem of multi drug
resistant P. falciparum malaria.
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